BioCardia Inc Share Price Nasdaq
Stocks
US09060U1016
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 06-05 | Top Midday Gainers | MT |
| 06-05 | BioCardia, Inc. Receives FDA Confirmation That CardiAMP HF II May Support Premarket Approval Of CardiAMP Cell Therapy For Ischemic HFrEF | CI |
| Market Cap | 9.48M 8.17M 7.52M 7.05M 13.25M 896M 13.38M 88.87M 34.71M 439M 35.56M 34.81M 1.52B | P/E Ratio 2026 * |
-1.23x | P/E Ratio 2027 * | -1.59x |
|---|---|---|---|---|---|
| Enterprise Value | 9.48M 8.17M 7.52M 7.05M 13.25M 896M 13.38M 88.87M 34.71M 439M 35.56M 34.81M 1.52B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
77.04% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BioCardia Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Peter Altman
CEO | Chief Executive Officer | 59 | 31/12/2001 |
David McClung
DFI | Director of Finance/CFO | 62 | 29/02/2016 |
| Chief Tech/Sci/R&D Officer | - | 31/07/2017 |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Altman
BRD | Director/Board Member | 59 | 31/12/2001 |
Jay Moyes
BRD | Director/Board Member | 72 | 31/12/2010 |
Simon Stertzer
CHM | Chairman | 90 | 31/12/2001 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 06-08 | Buy | Chief Executive Officer | 5,000 | 0.0440% | ||
| 05-19 | Buy | Chief Executive Officer | 1,500 | 0.0137% | ||
| 05-17 | Buy | Chief Executive Officer | 5,700 | 0.0521% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.18% | +0.24% | +57.28% | +108.28% | 54.92B | |
| -0.34% | +3.51% | +45.55% | +40.16% | 44.31B | |
| +0.29% | +6.20% | -14.80% | -19.65% | 22.96B | |
| -0.40% | +3.49% | -1.29% | +387.06% | 21.12B | |
| -3.30% | -0.20% | +12.75% | -37.03% | 16.31B | |
| -1.30% | -2.61% | +6.38% | -41.41% | 15.19B | |
| -0.24% | +2.44% | +27.43% | +177.49% | 13.32B | |
| +1.24% | +10.22% | +19.74% | - | 12.48B | |
| +0.32% | +2.81% | +96.37% | +213.49% | 11.21B | |
| Average | -0.38% | +2.75% | +27.71% | +103.55% | 23.54B | |
| Weighted average by Cap. | -0.37% | +2.86% | +32.08% | +95.19% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -9.07M -7.82M -7.2M -6.75M -12.68M -857M -12.81M -85.07M -33.23M -420M -34.04M -33.32M -1.45B | -10.02M -8.63M -7.94M -7.45M -14M -946M -14.14M -93.92M -36.69M -464M -37.58M -36.79M -1.6B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
